Efficacy of low-dose topotecan in second
β
Bo Gronlund; Heine H. Hansen; Claus HΓΈgdall; Svend A. Engelholm
π
Article
π
2002
π
John Wiley and Sons
π
English
β 82 KB
## Abstract ## BACKGROUND The high incidence of doseβlimiting myelosuppresion using the U.S. Food and Drug Administrationβapproved topotecan dose of 1.5 mg/m^2^ for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of th